I-Mab: Randomized Phase 2 Study of Uliledlimab in Combination With Pembrolizumab Plus Chemotherapy Expected to Begin in 1H 2025
天境生物:預計在2025年上半年開始的Uliledlimab與Pembrolizumab聯合化療的隨機2期研究
I-Mab: Randomized Phase 2 Study of Uliledlimab in Combination With Pembrolizumab Plus Chemotherapy Expected to Begin in 1H 2025
天境生物:預計在2025年上半年開始的Uliledlimab與Pembrolizumab聯合化療的隨機2期研究
譯文內容由第三人軟體翻譯。